Sugi Predict

Sugi Predict / Compounds / SCHEMBL23966923

SCHEMBL23966923

SCHEMBL23966923

Nc1ccc(-c2cn(C3CC3)c3ncnc(N)c23)cc1F

nearest known ligand 0.91

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 11/20 0.91
▸ SRC P12931 9/20 0.66
▸ ABL1 P00519 7/20 0.61
▸ EGFR P00533 7/20 0.61
▸ ABL2 P42684 7/20 0.61
▸ PDGFRB P09619 2/20 0.59
▸ KIT P10721 2/20 0.59
▸ FLT3 P36888 2/20 0.59
▸ JAK2 O60674 1/20 0.59
▸ NTRK1 P04629 1/20 0.59
▸ INSR P06213 1/20 0.59
▸ LCK P06239 1/20 0.59
▸ NPM1 P06748 1/20 0.59
▸ CSF1R P07333 1/20 0.59
▸ LYN P07948 1/20 0.59
▸ RET P07949 1/20 0.59
▸ IGF1R P08069 1/20 0.59
▸ MET P08581 1/20 0.59
▸ ROS1 P08922 1/20 0.59
▸ BCR P11274 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29998925 1.00 RIPK2 (0.91) RIPK2SRCABL1EGFRABL2
SCHEMBL29999326 0.95 RIPK2 (0.84) RIPK2SRCABL1EGFRABL2
SCHEMBL2075045 0.95 RIPK2 (0.84) RIPK2SRCABL1EGFRABL2
SCHEMBL23966761 0.95 RIPK2 (0.84) RIPK2SRCABL1EGFRABL2
SCHEMBL6108776 0.92 RIPK2 (0.78) RIPK2SRCABL1EGFRABL2
SCHEMBL6108780 0.92 RIPK2 (0.78) RIPK2SRCABL1EGFRABL2
SCHEMBL23966784 0.91 RIPK2 (0.77) RIPK2SRCABL1EGFRABL2
SCHEMBL29998920 0.91 RIPK2 (0.77) RIPK2SRCABL1EGFRABL2
SCHEMBL6108777 0.91 RIPK2 (0.77) RIPK2SRCABL1EGFRABL2
SCHEMBL6109524 0.90 RIPK2 (0.75) RIPK2SRCABL1EGFRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317758-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-09-26 — — US disclosed
US-12091413-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2024-09-17 — — US disclosed
EP-4146348-B1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2024-07-03 — — EP disclosed
CN-117597346-A NEK7 inhibitors 哈利亚治疗公司 2024-02-23 — — CN disclosed
EP-4320127-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-02-14 — — EP disclosed
US-20230416259-A1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2023-12-28 — — US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
CN-115843272-A Inhibitors of NEK7 kinase 哈利亚治疗公司 2023-03-24 — — CN disclosed
EP-4146348-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2023-03-15 — — EP disclosed
US-20220064173-A1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2022-03-03 — — US disclosed
WO-2021242505-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-02 — — WO disclosed
WO-2021242505-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-02 — — WO disclosed
US-20210355130-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2021-11-18 — — US disclosed
US-20210355130-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2021-11-18 — — US disclosed
WO-2021226547-A2 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. (US) 2021-11-11 — — WO disclosed
US-11161852-B1 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2021-11-02 — — US disclosed
US-11161852-B1 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2021-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355130-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-11713321-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-12091413-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 RIPK2 23/4885SRC 3388/4885ABL1 4556/4885
US-11161852-B1 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-20240317758-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 RIPK2 53/4885SRC 1649/4885ABL1 4219/4885
US-20230416259-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-20220064173-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.